Comparative animal study evaluates tirzepatide, semaglutide, and bariatric surgery in high-fat diet-fed rats, highlighting metabolic outcomes.
Bariatric surgery is a well-established treatment for obesity and type 2 diabetes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as a promising therapy for type 2 diabetes. This study aimed to compare the effects of bariatric surgery, semaglutide (a GLP-1 receptor agonist), and tirzepatide in Sprague-Dawley rats fed a high-fat diet.
No takes yet. Share an insight, caveat, or question.
Al‐Sabah et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: